Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer's Xeljanz Set To Lag Lilly's Olumiant In Europe Following Past Rebuffs

Executive Summary

Pfizer's Xeljanz (tofacitinib) has finally won a green light from the European Medicines Agency's CHMP for treating rheumatoid arthritis, but its two previous rejections by the panel on safety grounds might curb sales.

You may also be interested in...



Pfizer's Xeljanz: The Slow Road To Blockbuster Status

The oral pill, perhaps best known to investors for failing to live up to initial expectations in rheumatoid arthritis, has found its groove – and new opportunities in psoriatic arthritis and ulcerative colitis are on the horizon.

Baricitinib Complete Response May Put Lilly/Incyte Behind IL-6 Blockers In RA

FDA complete response letter seeks additional data on dosing and other safety concerns, delaying potential approval for an NDA that already had been pushed back three months. Interleukin-6 inhibitors sarilumab and sirukumab, now under review at FDA, both could obtain approval before baricitinib.

Ex-Pfizer Employee Overseeing Xeljanz Global Marketing Sued For Trade Secret Theft

Pfizer says its former global marketing director emailed and copied hundreds of documents on product launch plans and steps to obtain government approvals before leaving the company in January.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC098126

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel